The determinants of the adoption of pharmaceutical innovation: Evidence from Taiwan

Social Science and Medicine

Volumn 72, Issue 6, 2011, Pages 919-927

  Liu, Ya Ming ^a   Kao Yang, Yea Huei ^a   Hsieh, Chee Ruey ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b INSTITUTE OF ECONOMICS   (Taiwan)

Author keywords

Access to new drugs; Competition; Diabetes; National health insurance; Pharmaceutical innovation; Taiwan; Technology adoption

Indexed keywords

ACARBOSE; GLIMEPIRIDE; GLIQUIDONE; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE;

COMPETITION (ECONOMICS); DIABETES; DRUG; HEALTH INSURANCE; INNOVATION; TECHNOLOGY ADOPTION;

ARTICLE; BIOTECHNOLOGICAL PROCEDURES; CONCEPTUAL FRAMEWORK; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACEUTICAL ENGINEERING; PRESCRIPTION; SENSITIVITY ANALYSIS; TAIWAN;

AGED; DIABETES MELLITUS, TYPE 2; DIFFUSION OF INNOVATION; DRUG INDUSTRY; DRUG PRESCRIPTIONS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS; TAIWAN;

TAIWAN;

EID: 79953117559     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2010.12.027     Document Type: Article

References (27)

1. Baker L.C., Phibbs C.S. Managed care, technology adoption, and health care: the adoption of neonatal intensive care. RAND Journal of Economics 2002, 33:524-528.
2. Baker L.C. Managed care and technology adoption in health care: evidence from magnetic resonance imaging. Journal of Health Economics 2001, 20:395-421.
3. Bech M., Christiansen T., Dunham K., Lauridsen J., Lyttkens C.H., McDonald K., et al. The influence of economic incentives and regulatory factors on the adoption of treatment technologies: a case study of technologies used to treat heart attacks. Health Economics 2009, 18:1114-1132.
4. Berndt E. Pharmaceuticals in U.S. health care: determinants of quantity and prices. Journal of Economic Perspectives 2002, 16:45-66.
5. Chan J.C.N., Malik V., Jia W., Kadowaki T., Yajnik C.S., Yoon K.-H., et al. Diabetes in Asia: epidemiology, risk factors and pathophysiology. Journal of the American Medical Association 2009, 301:2129-2140.
6. Charlson M.E., Pompei P., Ales K.L., Mackenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987, 40:373-383.
7. Chou Y.J., Yip W.C., Lee C.-H., Huang N., Sun Y.-P., Chang H.-J. Impact of separating drug prescribing and dispensing on provider behavior: Taiwan's experience. Health Policy and Planning 2003, 18:316-329.
8. Chou S.Y., Liu J.T., Hammitt J.K. National health insurance and technology adoption: evidence from Taiwan. Contemporary Economic Policy 2004, 22:26-38.
9. Cutler D.M., Huckman R.S. Technological development and medical productivity: the diffusion of angioplasty in New York state. Journal of Health Economics 2003, 22:187-217.
10. Cutler D.M., McClellan M. Is technological change in medicine worth it?. Health Affair 2001, 20:11-29.
11. Dranove D., Shanley D., Simon C. Is hospital competition wasteful?. Rand Journal of Economics 1992, 23:247-262.
12. Dozet A., Lyttkens C.H., Nystedt P. Health care for the elderly: two cases of technology diffusion. Social Science & Medicine 2002, 54:49-64.
13. Ellison S.F., Snyder C.M. Countervailing power in wholesale pharmaceuticals. Journal of Industrial Economics 2010, 58:32-53.
14. Escarce J. Externalities in hospitals and physician adoption of a new surgical technology: an exploratory analysis. Journal of Health Economics 1996, 15:715-734.
15. Grabowski H.G., Wang Y.R. The quantity and quality of worldwide new drug introductions, 1982-2003. Health Affairs 2006, 25:452-460.
16. Hsieh C.R. Pharmaceutical policy in Taiwan. Prescribing cultures and pharmaceutical policy in the Asia-Pacific 2009, 109-125. Brookings Institution Press, Baltimore. K. Eggleston (Ed.).
17. Lichtenberg, F. R. (2009). The quality of medical care, behavior risk factors, and longevity growth. NBER Working Paper 15068.
18. Lin T., Chou P., Lai M.S., Tsai S.T., Tai T.Y. Direct cost-of-illness of patients with diabetes mellitus in Taiwan. Diabetes Research and Clinical Practice 2001, 54:S43-S46.
19. Liu Y.M., Kao Yang Y.H., Hsieh C.R. Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: evidence from Taiwan. Journal of Health Economics 2009, 28:341-349.
20. Markowitz S., Cuellar A. Antidepressants and youth: healing or harmful?. Social Science & Medicine 2007, 64:2138-2151.
21. Mas N., Seinfeld J. Is managed care restraining the adoption of technology by hospitals?. Journal of Health Economics 2008, 27:1026-1045.
22. McGuire T.G. Physician agency. Handbook of health economics 2000, 461-536. Elsevier, Amsterdam. A.J. Culyer, J.P. Newhouse (Eds.).
23. Newhouse J.P. Medical care costs: how much welfare loss?. Journal of Economic Perspectives 1992, 6:3-21.
24. Okunade A.A., Murthy V.N.R. Technology as a 'major driver' of health care costs: a cointegration analysis of the Newhouse conjecture. Journal of Health Economics 2002, 21:147-159.
25. Papageorgiou C., Savvides A., Zachariadis M. International medical technology diffusion. Journal of International Economics 2007, 72:409-427.
26. Sloan F.A. Not-for-profit ownership and hospital behavior. Handbook of health economics 2000, 1141-1174. Elsevier, Amsterdam. A.J. Culyer, J.P. Newhouse (Eds.).
27. Tsai Y.W., Wen Y.W., Huang W.F., Kuo K.N., Chen P.F., Shih H.W., et al. Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidiones for diabetes. European Journal of Health Economics 2010, 11:279-290.